Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 40 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Renal Care & Research from Walhain, company number BE0659994532, closed financial year 2025 with a result of € 56,921 after tax. For that financial year Renal Care & Research recorded a gross margin of € 261,423 and equity of € 371,658. Compared with financial year 2024, the result moved from € -56,424 to € 56,921. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.
€ 371,658
▲ 88% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 56,921
▲ still € 56,424 loss in 2024
Profit after tax over the fiscal year.
€ 895
▼ 91% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 122,411.
People and assets in 2025
€ 65,265
▲ € 59,911 vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 39,297
▼ 26% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 253,439
▼ 11% vs 2024
€ 36,527 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.
€ 72,725
▼ 45% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 9,160
▼ 43% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 110,875 | € 251,750 | € 175,990 | € 261,423 | ▲ 49% |
| Profit after taxes | € -7,258 | € 106,969 | € -56,424 | € 56,921 | ▲ € 113,346 |
| Equity | € 336,141 | € 443,110 | € 197,442 | € 371,658 | ▲ 88% |
| Total debts | € 589,450 | € 613,065 | € 622,593 | € 571,670 | ▼ 8% |
| Cash | € 208,964 | € 321,772 | € 10,261 | € 895 | ▼ 91% |
| Retained profit | € 14,944 | € 121,914 | € 65,490 | € 122,411 | ▲ 87% |
| Bank debt | € 298,302 | € 273,984 | € 284,850 | € 253,439 | ▼ 11% |
| Balance sheet total | € 925,591 | € 1,056,175 | € 820,035 | € 943,328 | ▲ 15% |
Key figures of Renal Care & Research, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Renal Care & Research?
What happened at Renal Care & Research in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 56,921. filed late Source: NBB ↗
- New establishment in Waterloo. KBO
- Agnieszka Pozdzik-Cheriha became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 7,258 loss in 2022 to € 56,921 profit in 2025.
Paid € 8,926 in corporate taxes since 2022.
Best year ever: 2023, with € 106,969 profit.
A new publication or filing at Renal Care & Research? We notify you, reason included.
Follow Renal Care & ResearchDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Renal Care & Research is Agnieszka Pozdzik-Cheriha.
Directors
According to the 2025 annual accounts
Agnieszka Pozdzik-Cheriha
Director
since 2016
Establishments
Establishment units
Physical locations of this company
Rue Saint-Martin(NSV) 35
1457 Walhain
Avenue des Pâquerettes 55 box 38
1410 Waterloo
Active since 28 July 2016
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0659.994.532
- VAT number
- BE 0659.994.532
- Registered office
- Rue Saint-Martin(NSV) 35, 1457 Walhain
- Names & denominations
- Renal Care & Research
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 July 2016
- Peppol
- Active · Active since 13 Dec 2025
- Contact
- 0032479951336
- Activities · NACE
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Detailhandel in ICT-apparatuur
Overige gespecialiseerde wetenschappelijke en technische activiteiten
Detailhandel in computers, randapparatuur en software in gespecialiseerde winkels
Speur- en ontwikkelingswerk op biotechnologisch gebied
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Verhuur en lease van kantoormachines, inclusief computers
Ontwerpen van computerprogramma’s
+6